References
- Kuhl H. Pharmacology of oestrogens and progestogens: influence of different routes of administration. Climacteric 2005; 8(Suppl 1)3–63
- Benagiano G, Primiero F M, Farris M. Clinical profile of contraceptive progestins. Eur J Contracept Reprod Health Care 2004; 9: 182–193
- Bloemenkamp K WM. Epidemiology of oral contraceptive related thrombosis. Thromb Res 2005; 115(Suppl)1–6
- Gomes M PV, Deitcher S R. Risk of venous thromboembolic disease associated with hormonal contraceptives and hormone replacement therapy. Arch Intern Med 2004; 164: 1965–1976
- Vasilakis-Scaramozza C, Jick H. Risk of venous thromboembolism with cyproterone or levonorgestrel contraceptives. Lancet 2001; 358: 1427–1429
- Conard J, Plu-Bureau G, Bahi N, et al. Progestogen-only contraception in women at high risk of venous thromboembolism. Contraception 2004; 70: 437–441
- Kuhnz W, Heuner A, Hümpel M, et al. In vivo conversion of norethisterone and norethisterone acetate to ethinyl estradiol in postmenopausal women. Contraception 1997; 56: 379–385
- Rosing J. Mechanisms of OC related thrombosis. Thromb Res 2005; 115(Suppl)81–83
- Kuhl H. Effects of progestogens on haemostasis. Maturitas 1996; 24: 1–19
- Tans G, Bouma B N, Büller H R, et al. Changes of hemostatic variables during oral contraceptive use. Sem Vasc Med 2003; 3: 61–68
- Wiegratz I, Lee J H, Kutschera E, Winkler U H, Kuhl H. Effect of four oral contraceptives on hemostatic parameters. Contraception 2004; 70: 97–106
- Herkert O, Kuhl H, Sandow J, Busse R, Schini-Kerth V B. Sex steroids used in hormonal treatment increase vascular procoagulant activity by inducing thrombin receptor (PAR-1) expression. Role of glucocorticoid receptor. Circulation 2001; 104: 2826–2831
- Godsland I F. Biology: risk factor modification by OCs and HRT – lipids and lipoproteins. Maturitas 2004; 47: 299–303
- Wiegratz I, Lee J H, Kutschera E, et al. Effect of dienogest-containing oral contraceptives on lipid metabolism. Contraception 2002; 65: 223–229
- Clarkson T B, Appt S E. Controversis about HRT – lessons from monkey models. Maturitas 2005; 51: 64–74
- Tanis B C, van den Bosch A AJ, Kemmeren J M, et al. Oral contraceptives and the risk of myocardial infarction. New Engl J Med 2001; 345: 1787–1793
- Oelkers W. Drospirenone, a progestogen with anti-mineralocorticoid properties: a short review. Mol Cell Endocrinol 2004; 217: 255–261
- Dubey R K, Oparil S, Imthurn B, Jackson E K. Sex hormones and hypertension. Cardiovasc Res 2002; 53: 688–708
- Machado R B, Tachotti F, Cavenague G, Maia E. Effects of two different oral contraceptives on total body water: a randomized study. Contraception 2006; 73: 344–347
- Wiegratz I, Kuhl H. Managing cutaneous manifestations of hyperandrogenic disorders. The role of oral contraceptives. Treat Endocrinol 2002; 1: 373–386
- Wiegratz I, Kutschera E, Lee J H, et al. Effect of four different oral contraceptives on various sex hormones and serum binding globulins. Contraception 2003; 67: 25–32